This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Chloramphenicol (chloromycetin®) has been accepted by the Council on Pharmacy and Chemistry for inclusion in New and Nonofficial Remedies. Its antibiotic properties are well known, and when the council accepted this product there was much evidence to demonstrate its therapeutic value. At the same time there then was little reason to believe that serious or fatal side-reactions would be demonstrated. Nevertheless, following a study of the chemical structure of the drug, the Council issued a warning at the time of acceptance even though there was meager evidence to prove that such a warning was necessary. Thus, on page 116 of New and Nonofficial Remedies, 1951, there appears the following statement:
"Changes in the peripheral blood or the blood-forming organs have been reported only during the use of chloramphenicol. Mild hemolytic anemias, granulocytopenia (no cases of agranulocytosis so far) and an arrest in the maturation of the formed elements in the
BLOOD DYSCRASIA FOLLOWING THE USE OF CHLORAMPHENICOL. JAMA. 1952;149(9):840. doi:10.1001/jama.1952.02930260042010
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: